Company Description
Decoy Therapeutics Inc. focuses on advancing the peptide conjugate therapeutics through its Immediate Peptide/PPMO/P-PROTAC Alpha-helical Conjugate Technology (IMP3ACT) platform that reduces the complexity of drug development and manufacturing.
Its IMP3ACT platform leverages machine learning and artificial intelligence tools alongside synthesis techniques to engineer, optimize, and manufacture peptide conjugates targeting various unmet medical needs.
The company focuses on building a portfolio of peptide conjugate therapeutics focusing on infectious diseases and oncology.
The company was formerly known as Salarius Pharmaceuticals, Inc. and change its name to Decoy Therapeutics Inc. in January 2026.
Decoy Therapeutics Inc. is based in Cambridge, Massachusetts.
| Country | United States |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 2 |
| CEO | Frederick Pierce |
Contact Details
Address: One Broadway, 14th Floor Cambridge, Massachusetts 02142 United States | |
| Website | decoytx.com |
Stock Details
| Ticker Symbol | DCOY |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001615219 |
| CUSIP Number | 79400X503 |
| ISIN Number | US79400X5032 |
Key Executives
| Name | Position |
|---|---|
| Frederick E. Pierce II | Chief Executive Officer and Director |
| Mark J. Rosenblum CPA | Executive Vice President and Chief Financial Officer |
| Dr. Barbara Hibner Ph.D. | Chief Scientific Officer and Director |
| Dr. Nadeem Q. Mirza M.D., M.P.H. | Senior Vice President of Clinical Development |
| Peter K. Marschel M.B.A., M.S. | Chief Business Officer |